Literature DB >> 16452358

Temporal associations among energy intake, plasma linoleic acid, and growth improvement in response to treatment initiation after diagnosis of cystic fibrosis.

Suzanne M Shoff1, Hong-Yup Ahn, Lisa Davis, HuiChuan Lai.   

Abstract

OBJECTIVE: It is unclear why some patients with cystic fibrosis (CF) succeed ("responders") in recovering from malnutrition and growth faltering after treatment initiation whereas others fail to do so ("nonresponders"). We conducted a study to test the hypothesis that sustained high energy intake (increased EN) and normal plasma essential fatty acid status are critical determinants of treatment responsiveness within 2 years after diagnosis of CF.
METHODS: A total of 71 CF children who had pancreatic insufficiency but not meconium ileus and were enrolled in the Wisconsin CF Neonatal Screening Project were studied. Responders were defined by having achieved adequate weight gain, as indicated by a recovery of weight z score (Wtz) comparable to Wtz at birth (WtzBR) within 2 years of diagnosis. Increased EN and sustained normal plasma linoleic acid level (increased pLA) were defined by achieving energy intake > or =120% of estimated requirement for > or =75% of the time and maintaining plasma LA > or =26% of total fatty acids for > or =75% of the time, respectively.
RESULTS: Thirty-two (68%) screened patients and 13 (54%) patients whose CF was diagnosed conventionally recovered WtzBR within 2 years of diagnosis. Screened patients responded at significantly younger ages (mean/median: 6.3/4.3 months) than patients whose CF was diagnosed conventionally (mean/median: 15.8/11.8 months). Proportionately fewer screened patients (33%) achieved increased EN compared with patients whose CF was diagnosed conventionally (73%). However, more screened patients responded to increased EN and recovered WtzBR (91%) than patients whose CF was diagnosed conventionally (56%), although this difference was of borderline significance. Compared with having neither increased EN nor increased pLA, the likelihood of being a responder was greatest with combined increased EN and increased pLA, followed by increased EN only. The positive associations between increased EN and increased pLA to treatment responsiveness remained significant after adjustment for neonatal screening status, baseline height and weight status, and indices of pulmonary disease severity.
CONCLUSION: Increased EN and increased pLA are critical in promoting adequate weight gain in children with newly diagnosed CF.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16452358     DOI: 10.1542/peds.2004-2832

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  20 in total

1.  Cystic fibrosis papers of the year 2009.

Authors:  Ian M Balfour-Lynn
Journal:  J R Soc Med       Date:  2010-07       Impact factor: 5.344

2.  Utilizing centralized biorepository samples for biomarkers of cystic fibrosis lung disease severity.

Authors:  Scott D Sagel; Brandie D Wagner; Assem Ziady; Tom Kelley; John P Clancy; Monica Narvaez-Rivas; Joseph Pilewski; Elizabeth Joseloff; Wei Sha; Leila Zelnick; Kenneth D R Setchell; Sonya L Heltshe; Marianne S Muhlebach
Journal:  J Cyst Fibros       Date:  2019-12-20       Impact factor: 5.482

3.  Effect of Oral Lipid Matrix Supplement on Fat Absorption in Cystic Fibrosis: A Randomized Placebo-Controlled Trial.

Authors:  Virginia A Stallings; Joan I Schall; Asim Maqbool; Maria R Mascarenhas; Belal N Alshaikh; Kelly A Dougherty; Kevin Hommel; Jamie Ryan; Okan U Elci; Walter A Shaw
Journal:  J Pediatr Gastroenterol Nutr       Date:  2016-12       Impact factor: 2.839

4.  Growth and pulmonary outcomes during the first 2 y of life of breastfed and formula-fed infants diagnosed with cystic fibrosis through the Wisconsin Routine Newborn Screening Program.

Authors:  Sarah A Jadin; Grace S Wu; Zhumin Zhang; Suzanne M Shoff; Benjamin M Tippets; Philip M Farrell; Tami Miller; Michael J Rock; Hara Levy; HuiChuan J Lai
Journal:  Am J Clin Nutr       Date:  2011-03-23       Impact factor: 7.045

5.  Pubertal Height Growth and Adult Height in Cystic Fibrosis After Newborn Screening.

Authors:  Zhumin Zhang; Mary J Lindstrom; Philip M Farrell; HuiChuan J Lai
Journal:  Pediatrics       Date:  2016-04-05       Impact factor: 7.124

6.  Pigs and humans with cystic fibrosis have reduced insulin-like growth factor 1 (IGF1) levels at birth.

Authors:  Mark P Rogan; Leah R Reznikov; Alejandro A Pezzulo; Nicholas D Gansemer; Melissa Samuel; Randall S Prather; Joseph Zabner; Douglas C Fredericks; Paul B McCray; Michael J Welsh; David A Stoltz
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-08       Impact factor: 11.205

7.  Recovery of birth weight z score within 2 years of diagnosis is positively associated with pulmonary status at 6 years of age in children with cystic fibrosis.

Authors:  Huichuan J Lai; Suzanne M Shoff; Philip M Farrell
Journal:  Pediatrics       Date:  2009-02       Impact factor: 7.124

8.  Early life growth patterns persist for 12 years and impact pulmonary outcomes in cystic fibrosis.

Authors:  Don B Sanders; Zhumin Zhang; Philip M Farrell; HuiChuan J Lai
Journal:  J Cyst Fibros       Date:  2018-02-01       Impact factor: 5.482

9.  Serum linoleic acid status as a clinical indicator of essential fatty acid status in children with cystic fibrosis.

Authors:  Asim Maqbool; Joan I Schall; J Felipe Garcia-Espana; Babette S Zemel; Birgitta Strandvik; Virginia A Stallings
Journal:  J Pediatr Gastroenterol Nutr       Date:  2008-11       Impact factor: 2.839

10.  Pubertal height velocity and associations with prepubertal and adult heights in cystic fibrosis.

Authors:  Zhumin Zhang; Mary J Lindstrom; HuiChuan J Lai
Journal:  J Pediatr       Date:  2013-03-25       Impact factor: 4.406

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.